News
Thu, 02 May 2024 05:37:00 -0400
Thu, 02 May 2024 05:37:00 -0400
Financial report for the period 1 January 2024 to 31 March 2024
PROFIT AND LOSS |
Q1 2024 |
Q1 2023 |
Growth as reported |
Growth at CER* |
USD million |
|
|
|
|
Net sales |
9,516 |
7,693 |
22% |
24% |
Operating profit |
4,638 |
3,605 |
27% |
30% |
|
|
|
|
|
Net profit |
3,700 |
2,856 |
28% |
N/A |
Diluted earnings per share (in USD) |
0.83 |
0.63 |
29% |
N/A |
* CER: Constant exchange rates (average 2023). ** For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.0 = DKK 6.86700 and the period-end exchange rate of USD 1.0 = DKK 6.89553. |
Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the sales growth in the first three months of 2024, driven by increased demand for our GLP-1-based diabetes and obesity treatments. More patients benefit from our innovative treatments, and the agreement to acquire the three Catalent manufacturing sites will enable us to serve significantly more people living with diabetes and obesity in the future. Within R&D, we are pleased with the positive results from the kidney outcomes trial with semaglutide and the label expansion for cardiovascular risk reduction for Wegovy® in the US."
On 2 May 2024 at 13.00 CEST, corresponding to 07.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.